

NEWS RELEASE



25th March 2019

Results of the PHOSPHASE study of iron isomaltoside 1000 in ENDO congress

Nippon Shinyaku Co., Ltd (HQ: Kyoto, President: Shigenobu Maekawa) announced today that Pharmacosmos A/S (HQ: Holbaek, Denmark, President & CEO: Lars Christensen) announced officially results of studies comparing iron isomaltoside 1000 to ferric carboxymaltose for the treatment of iron deficiency presented at the ENDO congress in New Orleans, USA on 24th March 2019

Pharmacosmos conducted the PHOSPHARE study program comprising two head-to-head studies comparing iron isomaltoside 1000 to ferric carboxymaltose and demonstrated evaluation of both products in relation to hypophosphatemia and other fibroblast growth factor (FGF)23-mediated effects. 245 patients were enrolled in PHOSPHARE study and the incidence, severity and duration of hypophosphatemia were investigated. Detailed information on the results shall be referred to the following Pharmacosmos website.
<https://www.pharmacosmos.com/news-media/news>

Nippon Shinyaku entered into a license agreement with Pharmacosmos on iron isomaltoside 1000 in December, 2016. In Japan, NS-32 (development code) is conducted for the patients with iron deficiency anaemia. An agent for the treatment of iron deficiency anaemia is expected to fulfil an unmet medical need in gynaecological therapeutic field. Nippon Shinyaku aims to contribute to improving treatment for patients with iron deficiency by launching iron isomaltoside 1000 in Japan as soon as possible.

About iron isomaltoside 1000

Iron isomaltoside 1000 (ferric derisomaltose, brand names Monofer® or Monoferric® in other countries) is an iron-carbohydrate complex for intravenous administration. Monofer® is marketed in more than 30 countries worldwide for the treatment of iron deficiency or iron deficiency anaemia.

About Nippon Shinyaku Co., Ltd.

Nippon Shinyaku, established in 1919, has a long-history as a research-oriented pharmaceutical company in Japan. It has been dedicated to research and development of innovative drugs. Nippon Shinyaku has been focusing on urology, hematology, intractable and rare diseases, as well as gynaecology and otorhinolaryngology. Nippon Shinyaku is striving to address unmet medical needs and launching pharmaceuticals to help patients. For further information, please refer to the company website: <http://www.nippon-shinyaku.co.jp/english/>

About Pharmacosmos A/S

Pharmacosmos A/S is a family-owned Danish pharmaceutical company headquartered in Holbaek, Denmark and has a history for more than 50 years regarding R&D of injectable iron formulation and carbohydrate. A research-based company, its ongoing R&D programme focuses on improving the lives of patients with iron deficiency with or without anaemia. More than 1 billion people live with iron deficiency anaemia and it is the leading cause of death for an estimated 180,000 people every year. This makes it one of the largest global health challenges of our time.

For further information, please refer to the company website:

<https://www.pharmacosmos.com/>